Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
2 recherche sur le mot-clé 'Pervasive developmental disorder-not otherwise specified'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Common and unique impairments in facial-expression recognition in pervasive developmental disorder-not otherwise specified and Asperger's disorder / Shota UONO in Research in Autism Spectrum Disorders, 7-2 (February 2013)
[article]
Titre : Common and unique impairments in facial-expression recognition in pervasive developmental disorder-not otherwise specified and Asperger's disorder Type de document : Texte imprimé et/ou numérique Auteurs : Shota UONO, Auteur ; Wataru SATO, Auteur ; Motomi TOICHI, Auteur Article en page(s) : p.361-368 Langues : Anglais (eng) Mots-clés : Asperger's disorder Facial expression recognition Pervasive developmental disorder Pervasive developmental disorder-not otherwise specified Index. décimale : PER Périodiques Résumé : This study was designed to identify specific difficulties and associated features related to the problems with social interaction experienced by individuals with pervasive developmental disorder-not otherwise specified (PDD-NOS) using an emotion-recognition task. We compared individuals with PDD-NOS or Asperger's disorder (ASP) and typically developing individuals in terms of their ability to recognize facial expressions conveying the six basic emotions. Individuals with PDD-NOS and ASP were worse at recognizing fearful faces than were controls. Individuals with PDD-NOS were less accurate in recognizing disgusted faces than were those with ASP. The results suggest that PDD subtypes are characterized by shared and unique impairments in the ability to recognize facial expressions. Furthermore, the ability to recognize fearful but not disgusted expressions was negatively correlated with the severity of social dysfunction in PDD-NOS and ASP. The results suggest that impaired recognition of fearful and disgusted faces may reflect the severity of social dysfunction across PDD subtypes and the specific problems associated with PDD-NOS, respectively. Characteristics associated with different levels of symptom severity in PDD-NOS are discussed in terms of similarities with brain damage and other psychiatric disorders. En ligne : http://dx.doi.org/10.1016/j.rasd.2012.10.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=186
in Research in Autism Spectrum Disorders > 7-2 (February 2013) . - p.361-368[article] Common and unique impairments in facial-expression recognition in pervasive developmental disorder-not otherwise specified and Asperger's disorder [Texte imprimé et/ou numérique] / Shota UONO, Auteur ; Wataru SATO, Auteur ; Motomi TOICHI, Auteur . - p.361-368.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 7-2 (February 2013) . - p.361-368
Mots-clés : Asperger's disorder Facial expression recognition Pervasive developmental disorder Pervasive developmental disorder-not otherwise specified Index. décimale : PER Périodiques Résumé : This study was designed to identify specific difficulties and associated features related to the problems with social interaction experienced by individuals with pervasive developmental disorder-not otherwise specified (PDD-NOS) using an emotion-recognition task. We compared individuals with PDD-NOS or Asperger's disorder (ASP) and typically developing individuals in terms of their ability to recognize facial expressions conveying the six basic emotions. Individuals with PDD-NOS and ASP were worse at recognizing fearful faces than were controls. Individuals with PDD-NOS were less accurate in recognizing disgusted faces than were those with ASP. The results suggest that PDD subtypes are characterized by shared and unique impairments in the ability to recognize facial expressions. Furthermore, the ability to recognize fearful but not disgusted expressions was negatively correlated with the severity of social dysfunction in PDD-NOS and ASP. The results suggest that impaired recognition of fearful and disgusted faces may reflect the severity of social dysfunction across PDD subtypes and the specific problems associated with PDD-NOS, respectively. Characteristics associated with different levels of symptom severity in PDD-NOS are discussed in terms of similarities with brain damage and other psychiatric disorders. En ligne : http://dx.doi.org/10.1016/j.rasd.2012.10.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=186 Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies / A. Y. HARDAN in Autism, 23-8 (November 2019)
[article]
Titre : Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies Type de document : Texte imprimé et/ou numérique Auteurs : A. Y. HARDAN, Auteur ; R. L. HENDREN, Auteur ; Michael G. AMAN, Auteur ; A. ROBB, Auteur ; R. D. MELMED, Auteur ; K. A. ANDERSEN, Auteur ; R. LUCHINI, Auteur ; R. RAHMAN, Auteur ; S. ALI, Auteur ; X. D. JIA, Auteur ; M. MALLICK, Auteur ; J. E. LATEINER, Auteur ; Rohan H. C. PALMER, Auteur ; S. M. GRAHAM, Auteur Article en page(s) : p.2096-2111 Langues : Anglais (eng) Mots-clés : Asperger's disorder Social Responsiveness Scale autism spectrum disorders clinical trial medication memantine pervasive developmental disorder-not otherwise specified randomized withdrawal school-age children Index. décimale : PER Périodiques Résumé : Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder. MEM-MD-91, a 50-week open-label trial, identified memantine extended-release treatment responders for enrollment into MEM-MD-68, a 12-week randomized, double-blind, placebo-controlled withdrawal trial. MEM-MD-69 was an open-label extension trial in which participants from MEM-MD-68, MEM-MD-91, and open-label trial MEM-MD-67 were treated 48 weeks with memantine extended release. In MEM-MD-91, 517 (59.6%) participants were confirmed Social Responsiveness Scale responders at week 12; mean Social Responsiveness Scale total raw scores improved two to three times a minimal clinically important difference of 10 points. In MEM-MD-68, there was no difference between memantine and placebo on the primary efficacy parameter, the proportion of patients with a loss of therapeutic response (defined as 10-point increase from baseline in Social Responsiveness Scale total raw score). MEM-MD-69 exploratory analyses revealed mean standard deviation improvement in Social Responsiveness Scale total raw score of 32.4 (26.4) from baseline of the first lead-in study. No new safety concerns were evident. While the a priori-defined efficacy results of the double-blind trial were not achieved, the considerable improvements in mean Social Responsiveness Scale scores from baseline in the open-label trials were presumed to be clinically important. En ligne : http://dx.doi.org/10.1177/1362361318824103 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=407
in Autism > 23-8 (November 2019) . - p.2096-2111[article] Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies [Texte imprimé et/ou numérique] / A. Y. HARDAN, Auteur ; R. L. HENDREN, Auteur ; Michael G. AMAN, Auteur ; A. ROBB, Auteur ; R. D. MELMED, Auteur ; K. A. ANDERSEN, Auteur ; R. LUCHINI, Auteur ; R. RAHMAN, Auteur ; S. ALI, Auteur ; X. D. JIA, Auteur ; M. MALLICK, Auteur ; J. E. LATEINER, Auteur ; Rohan H. C. PALMER, Auteur ; S. M. GRAHAM, Auteur . - p.2096-2111.
Langues : Anglais (eng)
in Autism > 23-8 (November 2019) . - p.2096-2111
Mots-clés : Asperger's disorder Social Responsiveness Scale autism spectrum disorders clinical trial medication memantine pervasive developmental disorder-not otherwise specified randomized withdrawal school-age children Index. décimale : PER Périodiques Résumé : Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder. MEM-MD-91, a 50-week open-label trial, identified memantine extended-release treatment responders for enrollment into MEM-MD-68, a 12-week randomized, double-blind, placebo-controlled withdrawal trial. MEM-MD-69 was an open-label extension trial in which participants from MEM-MD-68, MEM-MD-91, and open-label trial MEM-MD-67 were treated 48 weeks with memantine extended release. In MEM-MD-91, 517 (59.6%) participants were confirmed Social Responsiveness Scale responders at week 12; mean Social Responsiveness Scale total raw scores improved two to three times a minimal clinically important difference of 10 points. In MEM-MD-68, there was no difference between memantine and placebo on the primary efficacy parameter, the proportion of patients with a loss of therapeutic response (defined as 10-point increase from baseline in Social Responsiveness Scale total raw score). MEM-MD-69 exploratory analyses revealed mean standard deviation improvement in Social Responsiveness Scale total raw score of 32.4 (26.4) from baseline of the first lead-in study. No new safety concerns were evident. While the a priori-defined efficacy results of the double-blind trial were not achieved, the considerable improvements in mean Social Responsiveness Scale scores from baseline in the open-label trials were presumed to be clinically important. En ligne : http://dx.doi.org/10.1177/1362361318824103 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=407